Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  3. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • B Ejlertsen
  • J Aldridge
  • K V Nielsen
  • M M Regan
  • K L Henriksen
  • Anne Lykkesfeldt
  • S Müller
  • R D Gelber
  • K N Price
  • B B Rasmussen
  • G Viale
  • H Mouridsen
  • for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Vis graf over relationer
BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind23
Udgave nummer5
Sider (fra-til)1138-1144
ISSN0923-7534
DOI
StatusUdgivet - 10 okt. 2012

ID: 32774479